胰岛移植对1型糖尿病患者糖尿病并发症和死亡率的影响
这项回顾性多中心队列研究纳入61例单纯胰岛移植(ITA)受者与610例1型糖尿病对照、45例肾移植后胰岛移植(IAK)受者与45例对照,中位随访超过10年。与对照相比,ITA和IAK受者的复合结局风险更低(HR分别为0.39和0.52),ITA死亡率降低(HR 0.22)、IAK透析减少(HR 0.19),两组癌症风险均无显著变化。
要点
- 胰岛移植受者复合结局风险低于1型糖尿病对照(ITA的HR 0.39,IAK的HR 0.52)。
- ITA受者死亡风险降低(HR 0.22),IAK受者透析风险降低(HR 0.19)。
- 尽管使用免疫抑制剂,两组癌症风险均无显著变化。
核心结论
- 本研究提示胰岛移植对糖尿病相关结局具有长期益处,且未观察到癌症风险显著增加,总体风险-获益比有利。
研究设计与样本
- 回顾性、多中心队列研究,干预组来自三项胰岛移植临床试验,对照组来自法国国家健康数据系统(SNDS)理赔数据库。
- 纳入61例单纯胰岛移植(ITA)受者匹配610例1型糖尿病对照,45例肾移植后胰岛移植(IAK)受者匹配45例1型糖尿病对照,中位随访超过10年。
- 采用倾向性评分匹配,主要结局为包含死亡、透析、截肢、非致死性卒中、非致死性心肌梗死和短暂性脑缺血发作的复合终点,次要结局为癌症。
主要发现
- 与1型糖尿病对照相比,ITA受者复合结局风险更低(HR 0.39,95%CI 0.21-0.71,P=0.002),IAK受者复合结局风险也更低(HR 0.52,95%CI 0.30-0.88,P=0.014)。
- ITA受者死亡风险降低(HR 0.22,95%CI 0.09-0.54,P<0.001),IAK受者透析风险降低(HR 0.19,95%CI 0.07-0.50,P<0.001)。
- 两组癌症风险均无显著变化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the impact of islet transplantation (IT) on diabetes complications, death, and cancer incidence. RESEARCH DESIGN AND METHODS: This retrospective, multicenter, cohort study included patients from three IT clinical trials (intervention group) and from the French health insurance claims database Système National des Données de Santé (SNDS) (control group). Two cohorts of IT recipients were analyzed: IT recipients after kidney transplantation (IAK) and IT recipients alone (ITA). They were matched with patients living with type 1 diabetes (T1D) from the SNDS using a propensity score. The primary outcome was a composite criterion including death, dialysis, amputation, nonfatal stroke, nonfatal myocardial infarction, and transient ischemic attack. The secondary outcome was cancer. Hazard ratio (HRs) and P values were obtained using Cox proportional hazards analysis and log-rank test, respectively. RESULTS: The study included 61 ITA recipients matched to 610 T1D control patients and 45 IAK recipients matched to 45 T1D control patients over a median follow-up period >10 years. Compared with T1D control patients, ITA and IAK recipients had a lower composite outcome risk (HR 0.39 [95% CI 0.21-0.71; P = 0.002] and 0.52 [0.30-0.88; P = 0.014], respectively) that seemed driven by reduced mortality (0.22 [0.09-0.54]; P < 0.001) for ITA and reduced dialysis (0.19 [0.07-0.50]; P < 0.001) for IAK. Both groups showed no significant changes in cancer risk. CONCLUSIONS: This study suggests long-term benefits of IT on diabetes-related outcomes. Furthermore, despite the use of immunosuppressive drugs following IT, we observed no significant increase in the risk of cancer. Altogether, these findings highlight a favorable risk-benefit ratio of IT in treating patients with unstable T1D.
引用
- Perrier Q, Jambon-Barbara C, Kessler L, et al. Impact of Islet Transplantation on Diabetes Complications and Mortality in Patients Living With Type 1 Diabetes. Diabetes Care. 2025. PMID: 40245107. doi:10.2337/dc25-0059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。